SCHEMBL876396

SCHEMBL876396

C=CC(=O)OCC=CO.N=C=O.N=C=O

nearest known ligand 0.41

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TSHR P16473 7/20 0.41
ALDH1A1 P00352 4/20 0.41
TP53 P04637 3/20 0.41
HIF1A Q16665 3/20 0.41
CYP3A4 P08684 2/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HPGD P15428 1/20 0.37
THRB P10828 2/20 0.32
MAPT P10636 1/20 0.30
CACNA1B Q00975 1/20 0.30
APBA1 Q02410 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29156 0.90
SCHEMBL10608809 0.90
Ethylene SCHEMBL8677971 0.88 TSHR (0.46) TSHRALDH1A1TP53HIF1ACYP3A4
Charcoal, Activated SCHEMBL11360977 0.88 TSHR (0.46) TSHRALDH1A1TP53HIF1ACYP3A4
SCHEMBL2641211 0.84 TSHR (0.43) TSHRALDH1A1TP53HIF1ACYP3A4
Vinyl Chloride SCHEMBL10416733 0.84 TSHR (0.43) TSHRALDH1A1TP53HIF1ACYP3A4
Acrylic Acid SCHEMBL3666285 0.84 TSHR (0.43) TSHRALDH1A1TP53HIF1ACYP3A4
Toluene SCHEMBL10899737 0.84 THRB (0.41) TSHRALDH1A1TP53HIF1ACYP3A4
Urethane SCHEMBL17965916 0.83 ALOX15 (0.40) TSHRHPGD
Phosphoric Acid SCHEMBL16360251 0.82 TSHR (0.42) TSHRALDH1A1TP53HIF1ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113271934-B Composition for treating or preventing diabetic cataract 高丽大学校产学协力团 2024-05-28 CN disclosed
US-11938166-B2 Methods and compositions for treating mucosal tissue disorders THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-03-26 US disclosed
EP-4268843-A2 IMPROVED IL-6 ANTIBODIES F. Hoffmann-La Roche Ltd (CH) 2023-11-01 EP disclosed
US-20220169719-A1 IL-6 ANTIBODIES Sesen Bio, Inc. 2022-06-02 US disclosed
US-20220143129-A1 METHODS AND COMPOSITIONS FOR TREATING MUCOSAL TISSUE DISORDERS UNIV NORTH CAROLINA CHAPEL HILL (US) 2022-05-12 US disclosed
US-11154560-B2 Methods for treating ocular inflammatory diseases SUN PHARMA GLOBAL FZE (AE) 2021-10-26 US disclosed
US-11142571-B2 IL-6 antibodies Sesen Bio, Inc. (US) 2021-10-12 US disclosed
CN-113271934-A Composition for treating or preventing diabetic cataract 高丽大学校产学协力团 2021-08-17 CN disclosed
US-11058743-B2 Methods and compositions for treating mucosal tissue disorders THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2021-07-13 US disclosed
US-20210205330-A1 METHODS FOR TREATING OCULAR INFLAMMATORY DISEASES SUN PHARMA GLOBAL FZE (AE) 2021-07-08 US disclosed
EP-0536255-A4 OPHTHALMIC SUSPENSIONS 1993-07-07 EP disclosed
EP-0536255-A1 OPHTHALMIC SUSPENSIONS. INSITE VISION INC (US) 1993-04-14 EP disclosed
US-5192535-A Crosslinked polymers for delivery of drugs for eyes INSITE VISION INCORPORATED (US) 1993-03-09 US disclosed
WO-1992000044-A1 OPHTHALMIC SUSPENSIONS INSITE VISION INCORPORATED (US) 1992-01-09 WO disclosed
EP-0362321-A4 OPHTHALMIC SUSPENSIONS 1991-05-08 EP disclosed
EP-0362321-A1 OPHTHALMIC SUSPENSIONS. INSITE VISION INC (US) 1990-04-11 EP disclosed
WO-1989006964-A1 OPHTHALMIC SUSPENSIONS INSITE VISION, INC. (US) 1989-08-10 WO disclosed
EP-0222878-A4 AQUEOUS ALKALINE DEVELOPABLE, UV CURABLE URETHANE ACRYLATE COMPOUNDS AND COMPOSITIONS USEFUL FOR FORMING SOLDER MASK COATINGS. M & T CHEMICALS INC (US) 1987-09-02 EP disclosed
EP-0222878-A1 AQUEOUS ALKALINE DEVELOPABLE, UV CURABLE URETHANE ACRYLATE COMPOUNDS AND COMPOSITIONS USEFUL FOR FORMING SOLDER MASK COATINGS. M & T CHEMICALS INC (US) 1987-05-27 EP disclosed
WO-1986006730-A1 AQUEOUS ALKALINE DEVELOPABLE, UV CURABLE URETHANE ACRYLATE COMPOUNDS AND COMPOSITIONS USEFUL FOR FORMING SOLDER MASK COATINGS M&T CHEMICALS, INC. (US) 1986-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169719-A1 IL-6 ANTIBODIES IL6, IL6ST, IL2 TSHR 1328/4885ALDH1A1 1783/4885TP53 3304/4885
US-11142571-B2 IL-6 antibodies IL6, IL6ST, IL2 TSHR 1245/4885ALDH1A1 1869/4885TP53 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.